MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

436.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
73 74 Next >
News headline image
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy? ↗
Its pain medicine isn't precisely what it hoped for, but it could still sell. 
Via The Motley Fool
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs ↗
Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits. 
Via Benzinga
News headline image
Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients ↗
Vertex Pharmaceuticals' vanza triple program for cystic fibrosis, with superior results in lung function, sweat chloride reduction, and safety. 
Via Benzinga
News headline image
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest ↗
Its foray into developing analgesics seems to be going swimmingly. 
Via The Motley Fool
News headline image
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
This High-Flying Stock Just Got Some Bad News: Should You Sell? ↗
It's just a minor setback for this leading biotech. 
Via The Motley Fool
News headline image
Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat ↗
The company also topped fourth-quarter expectations. 
Via Investor's Business Daily
News headline image
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024 ↗
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
News headline image
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript ↗
VRTX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Earnings Preview: Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Key Takeaways From Vertex Pharmaceuticals Analyst Ratings ↗
 
Via Benzinga
News headline image
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? ↗
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for... 
Via Benzinga
Topics Economy
News headline image
Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024. 
Via Benzinga
News headline image
Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings ↗
As the market pushes higher despite the Federal Reserve's non-committal stance, traders fear a potential drawdown. 
Via Benzinga
Topics Economy
News headline image
Earnings Scheduled For February 5, 2024 ↗
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million. 
Via Benzinga
News headline image
Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week ↗
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500... 
Via Benzinga
Topics Stocks
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 3 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 29 through Feb. 2. 
Via Talk Markets
News headline image
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy? ↗
Vertex shares recently reached an all-time high. 
Via The Motley Fool
News headline image
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Should Quality Investors Include NASDAQ:VRTX in Their Portfolio? ↗
In this article we'll explore the quality characteristics of VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) 
Via Chartmill
News headline image
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements ↗
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio. 
Via InvestorPlace
News headline image
Biotech And Medtech Portfolio Notes On A Fed Day ↗
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23% 
Via Talk Markets
Topics Economy
News headline image
Buy Alert: 3 Stocks Sitting in the Sweet Spot ↗
They say timing is everything, so investors will want to take advantage of buying these stocks now instead of waiting. 
Via InvestorPlace
News headline image
Why Vertex Pharmaceuticals Stock Topped the Market Today ↗
The company reported that it met its primary endpoint in a study for its non-opioid pain drug. 
Via The Motley Fool
News headline image
Why Is Vertex Pharmaceuticals Stock Sliding Today? ↗
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery. 
Via Benzinga
News headline image
Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst ↗
The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal. 
Via Investor's Business Daily
News headline image
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story